Surgery rates in Japan around market-entry milestones of advanced therapies for Crohn’s disease and ulcerative colitis: an interrupted time-series study using a large-scale Japanese claims database

OBJECTIVE: Whether the market entry of newer advanced therapies is associated with changes in surgery rates for inflammatory bowel disease in routine clinical practice remains unclear. We aimed to describe surgery rates for Crohn's disease and ulcerative colitis in Japan around the market-entry milestones of advanced therapies. METHODS: This interrupted time-series study used a large-scale, outpatient-inclusive health insurance claims database from Japan (2012-2020). Prespecified intervention points were the market-entry months of ustekinumab for Crohn's disease (May 2017) and vedolizumab for ulcerative colitis (November 2018). The primary outcome was monthly surgery rates, modeled using segmented Poisson regression with an offset for patients at risk. RESULTS: The cohorts included 5,411 patients with Crohn's disease and 37,052 with ulcerative colitis. Surgery rates declined during the pre-intervention period (incidence rate ratios [95% confidence intervals]: Crohn's disease, 0.993 [0.988-0.999]; ulcerative colitis, 0.994 [0.988-1.001]). No evidence of a level or post-intervention trend change was observed at the intervention points (Crohn's disease: level change, 0.924 [0.708-1.202]; trend change, 1.000 [0.984-1.015]; ulcerative colitis: level change, 0.883 [0.588-1.309]; trend change, 1.008 [0.984-1.032]). CONCLUSION: Surgery rates showed a gradual pre-existing decline with no detectable level or trend change around these market-entry milestones. These findings suggest that changes in surgical rates may occur gradually rather than as an abrupt shift around a single market-entry milestone.

Authors

Institutions

Publication Details

Journal
Current Medical Research and Opinion
Published
2026-11-16
DOI
https://doi.org/10.1080/03007995.2026.2761162
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Surgery rates in Japan around market-entry milestones of advanced therapies for Crohn’s disease and ulcerative colitis: an interrupted time-series study using a large-scale Japanese claims database

Koji Kawakami, Mitsuhiro Mori, Takumi Kozu, Yoko M. Nakao
Current Medical Research and Opinion
Inflammatory Bowel Disease
article

Surgery rates in Japan around market-entry milestones of advanced therapies for Crohn’s disease and ulcerative colitis: an interrupted time-series study using a large-scale Japanese claims database

Koji Kawakami, Mitsuhiro Mori, Takumi Kozu, Yoko M. Nakao
article en

Abstract

OBJECTIVE: Whether the market entry of newer advanced therapies is associated with changes in surgery rates for inflammatory bowel disease in routine clinical practice remains unclear. We aimed to describe surgery rates for Crohn's disease and ulcerative colitis in Japan around the market-entry milestones of advanced therapies. METHODS: This interrupted time-series study used a large-scale, outpatient-inclusive health insurance claims database from Japan (2012-2020). Prespecified intervention points were the market-entry months of ustekinumab for Crohn's disease (May 2017) and vedolizumab for ulcerative colitis (November 2018). The primary outcome was monthly surgery rates, modeled using segmented Poisson regression with an offset for patients at risk. RESULTS: The cohorts included 5,411 patients with Crohn's disease and 37,052 with ulcerative colitis. Surgery rates declined during the pre-intervention period (incidence rate ratios [95% confidence intervals]: Crohn's disease, 0.993 [0.988-0.999]; ulcerative colitis, 0.994 [0.988-1.001]). No evidence of a level or post-intervention trend change was observed at the intervention points (Crohn's disease: level change, 0.924 [0.708-1.202]; trend change, 1.000 [0.984-1.015]; ulcerative colitis: level change, 0.883 [0.588-1.309]; trend change, 1.008 [0.984-1.032]). CONCLUSION: Surgery rates showed a gradual pre-existing decline with no detectable level or trend change around these market-entry milestones. These findings suggest that changes in surgical rates may occur gradually rather than as an abrupt shift around a single market-entry milestone.

Current Medical Research and Opinion
Kyoto University (JP)
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon